Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP

Marshall Wace LLP raised its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 83.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,499 shares of the biopharmaceutical company's stock after purchasing an additional 135,426 shares during the quarter. Marshall Wace LLP owned about 0.61% of Theravance Biopharma worth $2,523,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Bank of Montreal Can lifted its position in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock worth $1,414,000 after acquiring an additional 93,702 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Theravance Biopharma in the 2nd quarter valued at approximately $129,000. Hsbc Holdings PLC purchased a new position in shares of Theravance Biopharma during the 2nd quarter valued at approximately $108,000. Dimensional Fund Advisors LP grew its position in shares of Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company's stock worth $2,800,000 after buying an additional 91,679 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Theravance Biopharma by 11.7% in the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company's stock valued at $489,000 after acquiring an additional 6,026 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Analyst Upgrades and Downgrades

TBPH has been the subject of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 6th. TD Cowen decreased their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Leerink Partners cut Theravance Biopharma from an "outperform" rating to a "market perform" rating and cut their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, StockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Trading Down 0.2 %

TBPH stock traded down $0.02 during trading hours on Friday, hitting $8.08. 164,339 shares of the stock traded hands, compared to its average volume of 372,797. The stock has a 50-day simple moving average of $8.36 and a 200 day simple moving average of $8.82. The company has a market cap of $395.27 million, a P/E ratio of -9.42 and a beta of 0.24. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. During the same period in the prior year, the firm earned ($0.28) EPS. Analysts forecast that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In related news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the purchase, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction on Wednesday, August 7th. The stock was bought at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares of the company's stock, valued at $74,186,970. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 335,965 shares of the company's stock, valued at approximately $3,023,685. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.